Visit our USA website
PRESS RELEASE.
Re:Cognition Health is delighted to offer this new treatment
Re:Cognition Health is delighted with the announcement that the MHRA has approved Lecanemab, a pioneering treatment for Alzheimer’s disease. Starting in October 2024, this innovative therapy, also known as Leqembi™, will be available at Re:Cognition Health centres across the UK.
The Clarity trial, spearheaded by pharmaceutical giants Eisai and Biogen, enlisted 1,795 participants who were in the early stages of Alzheimer’s. Volunteers who received bi-weekly infusions of Lecanemab over 18 months, experienced and on average a 27% reduction in their rate of cognitive decline, compared to those who received a placebo.
Dr Emer MacSweeney, CEO, Medical Director, and Consultant Neuroradiologist at Re:Cognition Health, who also served as the Principal Investigator for the Clarity trial, said:
“Lecanemab’s approval by the MHRA represents a transformative moment in Alzheimer’s treatment. It is the first in a new era of targeted therapies, designed to modify the course of the disease. Leqembi™ is effective in clearing toxic amyloid protein from the brain, a key factor in Alzheimer’s that leads to memory loss and cognitive decline. By reducing the level of this toxic protein in the brain Lecanemab slowed cognitive deterioration, providing more time to enjoy a higher quality of life. This isn’t just a medical milestone, it’s a major advance towards making Alzheimer’s a treatable, and eventually, a preventable condition.”
As a global leader in clinical trials for Alzheimer’s and other neurodegenerative conditions, Re:Cognition Health is proud to contribute to this groundbreaking advancement. With clinics across the UK including in London, Birmingham, Bristol, Guildford, Plymouth and Winchester, as well as in several US cities, we are at the forefront of dementia research and patient care.
Re:Cognition Health’s extensive experience with Lecanemab, for treating early Alzheimer’s disease, sets us apart. Having administered over 2,033 Leqembi™ treatments and more than 9,000 IV infusions, within clinical trials, for other new medications of the same class as Leqembi™, our clinical team is extremely well qualified to carefully monitor the delivery of this new therapy in the UK.
One of our trial participants, David, has been receiving Lecanemab since 2020. His wife, Cheryl Essam, who has been closely involved in his care, shared her perspective:
“David was amongst the first patients in the UK to receive Lecanemab, with over 100 infusions to date. We’re honoured to have been part of this groundbreaking trial and believe it has made a real difference in slowing the progression of his disease.” (Read David’s story here)
As with all neurodegenerative conditions, early diagnosis is critical to accessing new treatments. The sooner intervention begins, the better the potential outcome. Leqembi™ will be available through Re:Cognition Health centres starting in October 2024.
For further information and to register interest call 0800 802 1030 or email clinician@re-cognitionhealth.com
To learn more, click here.
DISCLAIMER
Re:Cognition Health is unable to provide advice on personal medical matters. Please consult your doctor or other relevant health professional for specific, health-related advice and support.
Anyone who suspects they are having a side effect from this medicine is encouraged to talk to their doctor, pharmacist or nurse and report it directly to the Yellow Card scheme, either through the website (https://yellowcard.mhra.gov.uk/) or by searching the Google Play or Apple App stores for MHRA Yellow Card.
